RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Prophase Labs - Stock

Prophase Labs P/S 2024

Prophase Labs P/S

1.79

Ticker

PRPH

ISIN

US74345W1080

WKN

A1CYM1

As of Jun 20, 2024, Prophase Labs's P/S ratio stood at 1.79, a -49.58% change from the 3.55 P/S ratio recorded in the previous year.

The Prophase Labs P/S history

Prophase Labs Aktienanalyse

What does Prophase Labs do?

Prophase Labs Inc is a company focused on the development, manufacturing, and marketing of health products. It was founded in 1989 and is headquartered in Doylestown, Pennsylvania, USA. The business model of Prophase Labs is based on developing and selling innovative products in the health and wellness sector. The company specializes in three main areas: medical products, dietary supplements, and women's health through the TheaCare division. Medical products are mainly produced for the over-the-counter (OTC) market. OTC products are sold directly to consumers without a prescription. Prophase Labs offers products for pain relief, cough and cold, and sleep disorders. Dietary supplements are also distributed under the Cold-Eeze brand. The company offers various products such as gums, lozenges, and syrups for the treatment of cold and flu symptoms. These products are available in the USA and Canada. Prophase Labs' TheaCare division specializes in women's health. The products range from hygiene items to menstrual pain relievers to supplements for menopause. One well-known product is Zicam, a nasal spray designed to reduce cold and flu symptoms. It has been manufactured by Prophase Labs since 1999. The company has also dealt with the Federal Drug Administration (FDA) and other regulatory agencies in the past. In 2009, the company had to pay a fine for distributing unauthorized medications. In 2018, Prophase Labs changed its strategy to focus on developing dietary supplements and medical products for the health and wellness market. The company plans to increase its online distribution and expand its sales activities to other countries. The current challenges for Prophase Labs include competition from large pharmaceutical companies and other health sector companies. The industry is heavily regulated, which can make it difficult to introduce new products and expand into new markets. Additionally, the company is also facing declining revenues in some business areas. Overall, Prophase Labs is a company specializing in the manufacturing and sale of health products. With its various divisions and products, the company has the opportunity to reach customers in different areas. Despite facing challenges, it remains an important player in the health and wellness market. Prophase Labs ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Prophase Labs's P/S Ratio

Prophase Labs's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Prophase Labs's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Prophase Labs's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Prophase Labs’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Prophase Labs Stock

What is the price-to-earnings ratio of Prophase Labs?

The price-earnings ratio of Prophase Labs is currently 1.79.

How has the price-earnings ratio of Prophase Labs changed compared to last year?

The price-to-earnings ratio of Prophase Labs has increased by -49.58% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Prophase Labs high compared to other companies?

Yes, the price-to-earnings ratio of Prophase Labs is high compared to other companies.

How does an increase in the price-earnings ratio of Prophase Labs affect the company?

An increase in the price-earnings ratio of Prophase Labs would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Prophase Labs affect the company?

A decrease in the price-earnings ratio of Prophase Labs would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Prophase Labs?

Some factors that influence the price-earnings ratio of Prophase Labs are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Prophase Labs pay?

Over the past 12 months, Prophase Labs paid a dividend of 0.6 USD . This corresponds to a dividend yield of about 13.33 %. For the coming 12 months, Prophase Labs is expected to pay a dividend of 0 USD.

What is the dividend yield of Prophase Labs?

The current dividend yield of Prophase Labs is 13.33 %.

When does Prophase Labs pay dividends?

Prophase Labs pays a quarterly dividend. This is distributed in the months of January, June, March, June.

How secure is the dividend of Prophase Labs?

Prophase Labs paid dividends every year for the past 2 years.

What is the dividend of Prophase Labs?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prophase Labs located?

Prophase Labs is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prophase Labs kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prophase Labs from 6/3/2022 amounting to 0.3 USD, you needed to have the stock in your portfolio before the ex-date on 5/24/2022.

When did Prophase Labs pay the last dividend?

The last dividend was paid out on 6/3/2022.

What was the dividend of Prophase Labs in the year 2023?

In the year 2023, Prophase Labs distributed 0.6 USD as dividends.

In which currency does Prophase Labs pay out the dividend?

The dividends of Prophase Labs are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Prophase Labs

Our stock analysis for Prophase Labs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prophase Labs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.